38 Jermyn Street
About GammaDelta TherapeuticsGammaDelta Therapeutics is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident ?d T cells for effective immunotherapy.
Founder and Interim CEO: Raj Mehta
8 articles with GammaDelta Therapeutics
GammaDelta Therapeutics Receives FDA Clearance of IND Application for GDX012, a Novel Allogeneic Variable Delta 1 Gamma-delta T Cell Cancer Therapy
GammaDelta Therapeutics, a company focussed on exploiting the unique properties of gamma delta T cells for immunotherapy, announced the U.S. Food and Drug Administration has cleared the Investigational New Drug application for the Company’s allogeneic variable delta 1 gamma-delta T cell therapy, GDX012, to be investigated as a treatment for haematological malignancies.
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells
GammaDelta Therapeutics spins-out new company to accelerate antibody-based assets towards clinical studies
Adaptate will build on GammaDelta’s expertise in modulating gammadelta T-cell activity using antibodies, with a focus on developing an immune response to cancer.
GammaDelta Therapeutics announces Publication of New Data in Nature Immunology describing the Independent Immune Function of gamma delta (γδ) T cell receptors
Findings support development of γδ T cells for gastrointestinal diseases